Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
12/2005
12/29/2005US20050287595 obtaining a sample from a patient; conducting mass spectrometric analysis on the sample in a manner effective to maximize analysis of peptide fragments contained therein and comparing mass spectrum profiles of biopolymer marker and sample peptide
12/29/2005US20050287594 Activity-based probes having specificity to the active form of enzymes and receptors; screening for desired biological activities or target proteins
12/29/2005US20050287588 Breast cancer specific gene 1
12/29/2005US20050287584 Secreted proteins encoded by human chromosome 13
12/29/2005US20050287582 Antibodies that specifically bind to FDF03
12/29/2005US20050287580 Isolating biological modulators from biodiverse gene fragment libraries
12/29/2005US20050287579 Genes for male accessory gland proteins in Drosophila melanogaster
12/29/2005US20050287569 For therapy and diagnosis of Escherichia coli infections
12/29/2005US20050287564 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
12/29/2005US20050287554 Regions of papilloma virus E1 helicase involved in E1 oligomerization
12/29/2005US20050287545 Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
12/29/2005US20050287542 Avian pancreatic polypeptide comprising antigenic specificity for use in treatment and prevention of allergies, infection, inflammation, autoimmune and tumor disorders
12/29/2005US20050287530 TCL-1b gene and protein and related methods and compositions
12/29/2005US20050287529 Flea and tick octopamine receptor nucleic acid molecules, proteins and thereof
12/29/2005US20050287525 bioassay for testing peptides that bind to domain peptides of human immunodeficiency virus type I (HIV-1); peptides used for treating viral diseases
12/29/2005US20050287521 Oligonucleotides from sequences coding for the surface component of ptlv envelope proteins and uses thereof
12/29/2005US20050287517 Modulator of sweet or umami taste using ligand binding assay; detecting change in conformation
12/29/2005US20050287176 Dna sequences that encode antigens, cloning expression proteins serological diagnosis of canine leishmaniosis and proteins with Chemical intermediates
12/29/2005US20050287174 Immunizing against HIV infection
12/29/2005US20050287172 Influenza hemagglutinin and neuraminidase variants
12/29/2005US20050287171 bovine viral diarrhea virus; point mutations; glycoproteins; RNAse inhibition
12/29/2005US20050287170 Subunit vaccine against West Nile viral infection
12/29/2005US20050287169 Methods of use of genes of pyridoxal 5'-phosphate biosynthesis in Bacillus subtilis: avirulent strains for vaccines, and methods for identification of antibacterial agents
12/29/2005US20050287167 Polycistronic HIV vector constructs
12/29/2005US20050287166 Malarial pre-erythrocytic stage polypeptide molecules
12/29/2005US20050287165 Meningococcal antigens
12/29/2005US20050287164 Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections
12/29/2005US20050287163 Mycoplasma polypeptides
12/29/2005US20050287161 Vaccine
12/29/2005US20050287160 Useful for treatment and prevention of prostate cancer, especially when associated with bone metastases; also a cytotoxic T lymphocyte that specifically recognizes complex of HLA-A24 antigen and the cancer antigen peptide
12/29/2005US20050287159 Treatment methods for eotaxin mediated inflammatory conditons
12/29/2005US20050287158 The p65 subunit of nf-kb for the radiosensitization of cells
12/29/2005US20050287151 Secreted protein therapeutics and uses thereof
12/29/2005US20050287148 Monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
12/29/2005US20050287147 Cancer-linked gene as target for chemotherapy
12/29/2005US20050287144 For the modulation of signal activities controlled by NF-kappa B-inducing kinase (NIK); cancer , rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, asthma, cardiac infarct, Alzheimer's disease, or atherosclerosis
12/29/2005US20050287143 antibodies against such VEGFs, which may be used to inhibit their action, for example, to inhibit the growth of tumors, to treat diabetic retinopathy, rheumatoid arthritis and psoriasis
12/29/2005US20050287139 Wound healing
12/29/2005US20050287135 Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
12/29/2005US20050287123 DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
12/29/2005US20050287116 Use in suicide gene therapy of cancer cells and producing immunotoxins; infecting the cell with an adenovirus produced by a packaging cell line, where an adenoviral vector of a promoter is linked to a nucleic acid encoding the A subunit of diphtheria toxin A or Pseudomonas Exotoxin A, mutated EF-2 gene
12/29/2005US20050287098 Compositions and methods for controlling hair growth
12/29/2005US20050287072 Administering a conjugate of a biocompatible entity and a light-generating moiety; and measuring photon emission through an opaque tissue of said mammalian subject from the light-generating moiety; used for tracking the progression of infection
12/29/2005DE102004025805A1 Cosmetic compound for incorporation in pharmaceutical products for treatment of e.g. human skin, hair and nails
12/29/2005DE102004024617A1 Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung Differentially expressed in tumors gene products and their use
12/29/2005DE102004022574A1 Pharmaceutical formulation, for use in inflammatory disorders, identifies the rabies virus protein P as an interferon antagonist with substitution of the P-coded nucleic acid sequence
12/29/2005CA2735315A1 Plastid transit peptides
12/29/2005CA2734716A1 Plastid transit peptides
12/29/2005CA2734624A1 Plastid transit peptides
12/29/2005CA2734561A1 Plastid transit peptides
12/29/2005CA2575101A1 Pegylation of vasoactive intestinal peptide (vip)/pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use
12/29/2005CA2572171A1 Use of dna molecule as vaccine adjuvant
12/29/2005CA2571517A1 Uses of gpr100 receptor in diabetes and obesity regulation
12/29/2005CA2570508A1 Preparation of protective antigen from bacillus anthracis
12/29/2005CA2570500A1 Ultrasonic treatment of skin conditions or disorders, cancer as well as muscular/skeletal regeneration
12/29/2005CA2570267A1 Fgfr binding peptides
12/29/2005CA2570218A1 Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus
12/29/2005CA2570171A1 Methods of making nanotechnological and macromolecular biomimetic structures
12/29/2005CA2570130A1 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof
12/29/2005CA2569867A1 Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation
12/29/2005CA2569807A1 Oligomeric peptides and their use for the treatment of hiv infections
12/29/2005CA2569311A1 Stable isotope labeled polypeptide standards for protein quantitation
12/29/2005CA2568788A1 Production of polypeptides by improved secretion
12/29/2005CA2568601A1 Peptide-based compounds
12/29/2005CA2568543A1 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
12/29/2005CA2568384A1 Immune response suppressor and treatment of multiple sclerosis
12/29/2005CA2567686A1 Use of vegf inhibitors for the treatment of human cancer
12/29/2005CA2566620A1 Vaccine against hpv16 and hpv18 and at least another hpv type slected from hpv 31, 45 or 52
12/28/2005EP1609867A1 Nucleic acid construct, expression vector and method for enhancing the production of recombinant protein
12/28/2005EP1609865A2 Hepatitis B virus (HBV) variants
12/28/2005EP1609864A2 Use of neuronal apoptosis inhibitor protein (NAIP)
12/28/2005EP1609863A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same
12/28/2005EP1609862A1 Diabetes-mediating proteins and therapeutic uses thereof
12/28/2005EP1609861A1 Low-molecular weight peptides inhibiting ion channel activity
12/28/2005EP1609860A1 Seb modification and preventive/remedy for diseases with immune abnormality contianing the same
12/28/2005EP1609858A1 Branched neutral amino acid transporters acting as single molecule
12/28/2005EP1609856A2 Brain or heart cyclic nucleotide gated ion channel compounds and uses thereof
12/28/2005EP1609855A1 Process for producing plant storage organ with high production of recombinant protein and novel recombinant protein
12/28/2005EP1609853A1 Process for controlling sialylation of proteins produced by mammalian cell culture
12/28/2005EP1609802A1 Transcriptional factor inducing apoptosis in cancer cell
12/28/2005EP1609801A1 Proteins of natural origin and materials made therefrom
12/28/2005EP1609485A1 Method for the inactivation of viral components of protein-containing biological compositions
12/28/2005EP1609484A1 Cancer treatment with endothelin receptor antagonists
12/28/2005EP1609482A1 Drug for treating hemophilia and method of treating hemophilia using the same
12/28/2005EP1609478A1 Exendin agonist peptide formulations
12/28/2005EP1608983A2 Materials and methods for modulating cell motility
12/28/2005EP1608977A1 Nanoparticle for bioaffinity assays
12/28/2005EP1608970A2 Ccn3 compositions and methods
12/28/2005EP1608968A1 Assessment method
12/28/2005EP1608967A2 Compositions and methods for the diagnosis and treatment of tumor
12/28/2005EP1608962A2 Model for neurodegenerative disorders
12/28/2005EP1608782A2 Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
12/28/2005EP1608767A2 Optimized expression of hpv 31 l1 in yeast
12/28/2005EP1608762A2 Improved alphavirus replicons and helper constructs
12/28/2005EP1608756A2 Staphylococcus epidermidis antigens
12/28/2005EP1608741A2 Infectious bursal disease virus mutants and vaccines
12/28/2005EP1608736A2 Polynucleotide encoding a novel trp channel family member, ltrpc3, and splice variants thereof
12/28/2005EP1608730A2 Truncated baff receptors
12/28/2005EP1608685A2 Methods of treating diabetes by blocking vegf-mediated activity
12/28/2005EP1608683A1 Antibodies directed against hepatitis c virus e1e2 complex, compositions of hcv particles, and pharmaceutical compositions
1 ... 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 ... 2916